Key facts
- This page summarizes GSK plc's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Sep 2022, 16:16.
GSK plc - 16 Sep 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)
- Reporting relationship
- Former 10% Owner
- Issuer ticker
- TBPH
- Reported as of
- 16 Sep 2022
- Net transaction value
- +$175,024,132
- SEC form
- 4
- Accepted by SEC
- 20 Sep 2022, 16:16:05 UTC
- Prior SEC filing
- 06 Jul 2021
- Next SEC filing
- 14 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Victoria A. Whyte
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
GSK plc filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 20 Sep 2022.
Change
- Previous filing in this sequence was filed on 06 Jul 2021.
- Current net transaction value: +$175,024,132.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TBPH
transaction
Ordinary Shares
Other
- Transaction value
- $94,036,868
- Shares
- -9,644,807
- Change %
- -100%
- Price
- $9.75
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- By Corporation
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TBPH
transaction
Derivative
Exchangeable Senior Notes due 2023
Other
- Transaction value
- $269,061,000
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- See Footnote
- Underlying class
- Ordinary Shares
- Underlying amount
- 9,256,882
- Exercise price
- $29.07
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc ("GSK Finance"), a wholly owned indirect subsidiary of GSK plc ("GSK"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding.
Footnote F2
All 9,644,807 Ordinary Shares previously held by GSK were sold back to Theravance Biopharma pursuant to a Stock Repurchase Agreement dated September 16, 2022.